Multiple sclerosis Archives

santhera multiple sclerosis trial idebenone

News and Trends 5 Mar 2018

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that a first clinical trial in patients with primary progressive multiple sclerosis (PPMS) failed to prove the company’s drug to have any effect on the progression of […]

March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 4 Jan 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […]

January 4, 2018 - 2 minutesmins - By Alex Dale

topas therapeutics timm jessen interview

Interview 15 Nov 2017

Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them

In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas Therapeutics to hear about the company’s nanoparticles. Founded in 2013 as a spinout from Evotec, Topas Therapeutics is developing nanoparticles for a whole range of diseases and with CEO Timm Jessen at the helm. He told me the story of […]

November 15, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […]

November 1, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Nov 2017

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […]

November 1, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of Vienna have identified a target for the treatment of multiple sclerosis (MS). The research, published in the Journal of Autoimmunity, found that histone deacetylases (HDACs) play […]

October 19, 2017 - 3 minutesmins - By Alex Dale

bc platforms biogen microsoft multiple sclerosis

News and Trends 16 Oct 2017

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has built a platform to facilitate access to and analysis of large volumes of genomic and clinical data. Since September, the company has been collaborating with Microsoft, […]

October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Apitope Multiple Sclerosis ATX MS 1467 phase IIa 1

News and Trends 21 Feb 2017

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed promising results for the treatment of multiple sclerosis. Multiple sclerosis (MS) is a hot topic these days. While a recent long-term study revealed the potential of hematopoietic stem cell transplantation for the treatment of MS, this treatment strategy is […]

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

January 26, 2017 - 2 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us